intestinal development Articles
-
Development of new levodopa treatment strategies in Parkinson`s disease-from bedside to bench to bedside
Abstract This review will illustrate the process of moving from an idea through preclinical research and Galenic developments into clinical investigations and finally to approval by regulatory agencies within the European Union. The two new treatment strategies described, levodopa/carbidopa intestinal gel and levodopa/carbidopa microtablets, for advanced Parkinson's disease, have been ...
By Sensidose AB
-
Cyclin D1 Genetic Heterozygosity Regulates Colonic Epithelial Cell Differentiation and Tumor Number in ApcMin Mice
Constitutive ß-catenin/Tcf activity, the primary transforming events in colorectal carcinoma, occurs through induction of the Wnt pathway or APC gene mutations that cause familial adenomatous polyposis. Mice carrying Apc mutations in their germ line (ApcMin) develop intestinal adenomas. Here, the crossing of ApcMin with cyclin D1–/– mice reduced the intestinal tumor number in animals genetically ...
-
Function and Detection of Bile Acids
What is Bile Acid? Bile acids are the main components of bile and are synthesized in the liver from cholesterol through a series of enzymatic reactions. Bile acids can be divided into free bile acids and conjugated bile acids according to their structures. Free bile acids include bile acids, goose deoxycholic acid, deoxycholic acid and lithophanic acid. The above free bile acids are combined ...
-
Somatic and gastro‐intestinal in vivo biotransformation rates of hydrophobic chemicals in fish
To improve current bioaccumulation assessment methods, a methodology is developed, applied and investigated for measuring in vivo biotransformation rates of hydrophobic organic substances in the body (soma) and gastro‐intestinal tract of the fish. The method resembles the bioaccumulation OECD 305 dietary test but includes reference chemicals to determine both somatic and gastro‐intestinal ...
-
Novel nanoplatform for oral delivery of anti–cancer biomacromolecules
Oral administration of bio–macromolecules is an uphill task and the challenges from varying pH and enzymatic activity are difficult to overcome. In this regard, nanotechnology promises the new hope and offers advantages such as controlled release, target specific delivery, combinatorial therapy and many more. In this study, we demonstrate the formulation of a novel alginate enclosed, chitosan ...
-
Differential transcriptional response of bifidobacterium longum to human milk, formula milk, and galactooligosaccharide
In order to gain insight into the effects of human breast milk on the development of the intestinal bifidobacteria and associated health effects, the transcriptome of Bifidobacterium longum LMG 13197 grown in breast milk and formula milk containing galactooligosaccharides (GOS) and long-chain fructooligosaccharides was compared to that obtained in a semisynthetic medium with glucose. Total RNA ...
-
Exploring the Intricate Link Between Bile Acids and Disease
Bile acids are synthesized in the liver from cholesterol as a raw material. As a natural "emulsifier", they can promote the dissolution, digestion and absorption of fats, fat-soluble vitamins, etc. Meanwhile, as an important signaling molecule, bile acids can activate the relevant receptors to maintain the homeostasis of hepatic glucose and lipid metabolism, and interact with gut bacteria to ...
-
The Power Of RepliGut in Vitro Intestinal Stem Cell Models
Both current in vitro and in vivo models used in the development of candidate therapies for the treatment of intestinal diseases have severe limitations. RepliGut®, an in vitro human intestinal epithelial stem cell model, addresses many of these issues and has significant potential to reduce the time and cost of drug development. This model may even help to identify optimal therapies for ...
-
Enhancing Human Gut Tissue Models through Gene Editing
The variety of normal and diseased human tissues needed to perform comprehensive screening of drug candidates is a key resource for next-generation preclinical models, but obtaining these tissues is challenging. Gene editing enables Altis Biosystems to offer a diverse array of RepliGut® human gut models tailored for specific research programs. Many Challenges Around Accessing Tissues ...
-
Applications of 16S/18S/ITS Amplicon Sequencing
16S/18S/ITS amplicon sequencing has now been a well-established method. Due to its low cost, shorter cycle and low quality requirement of the sample, 16S/18S/ITS amplicon sequencing is widely used in the study of microorganisms. 16S/18S/ITS amplicon sequencing reveals the species of microorganisms in environmental samples and their differences, relative abundance, population structure and ...
By CD Genomics
-
Recapitulating the Multifaceted Inflammatory Environment of the Intestine In Vitro
Intestinal inflammatory diseases are highly complex, which has thus far prevented development of an effective in vitro disease model. With access to a donor-derived cell biobank and the ability to recapitulate region-specific environments of the intestine, Altis Biosystems is working toward the development of an in vitro RepliGut® model to accurately recapitulate the complex intestinal ...
-
Developing a Robust in Vitro Intestinal Model for Preclinical Candidate Screening of GI Toxicity
Gastrointestinal (GI) issues are common side effects of many drugs. Anticipating such side effects before clinical trials is limited by a lack of effective models for evaluating preclinical candidates for their potential to cause diarrhea, nausea, and other gut-related side effects. With its RepliGut® in vitro human intestinal model, Altis Biosystems is developing a system that could help ...
-
Increasing the Efficiency of Drug Development with Preclinical Testing Using Human Intestinal Stem Cells
Due to a lack of robust in vivo gut models, animal studies are generally required to evaluate gut toxicity. However, these studies can be lengthy and expensive and may not accurately recapitulate the behavior of the human gastrointestinal tract. Drugs are thus often developed with undesired gut side effects that are not apparent until clinical trials. Organ-on-a-chip models are the closest ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you